VEGFA and ovarian neoplasm: Since exacerbated angiogenesis is a crucial characteristic of EOC cells and VEGF-A is the most expressed angiogenic factor in ovarian tumours, a therapy based on a human monoclonal antibody against VEGF-A seems promissory for EOC treatment.